BRCA1 c.4987-3C>G is a pathogenic mutation by Brandão, Rita D. et al.
LETTER TO THE EDITOR
BRCA1 c.4987-3C>G is a pathogenic mutation
Rita D. Branda ˜o • Kees E. P. van Roozendaal •
Demis Tserpelis • Beppy Caanen •
Encarna Go ´mez Garcı ´a • Marinus J. Blok
Received: 4 November 2011/Accepted: 7 November 2011/Published online: 24 November 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
To the Editor,
In our previously published article by Branda ˜o et al. [1], we
reported that the unclassiﬁed variant (UV) BRCA1 c.4987-
3C[G gives rise to BRCA1D17. However, since we could
not exclude residual expression of the full-length transcript
from the variant allele, we have classiﬁed the variant as
likely pathogenic. We now have evidence that the variant is
indeed pathogenic.
Allele-speciﬁc PCRs are useful to determine the relative
contribution of each allele to the synthesis of full-length or
alternative transcripts. This can be achieved with, for
instance, Sanger sequencing of the RT-PCR products and
the use of a heterozygous variant to establish allelic
expression ratios [1]. Unfortunately, in this family neither
the proband nor the relatives tested for the BRCA1 c.4987-
3C[G variant were heterozygous for a polymorphism in
the region of the spliced exon. Since the UV is not exonic,
it could not be used to determine allelic expression. Con-
sequently, in our previously published article, using
RT-PCRs on RNA isolated from primary cultured lym-
phocytes, we failed to determine whether the UV allele was
still giving rise to some full-length BRCA1 transcript. To
establish the pathogenicity of this variant, we performed an
additional study using an ex vivo assay based on a splicing
reporter minigene. We selected the exon-trapping vector
pSPL3b [2] (a kind gift from Dr. R Sedlmeier, Ingenium
Pharmaceuticals GmbH), previously used for similar
studies [3–5]. Initially, BRCA1 exon 17 was ampliﬁed
including the surrounding intronic regions from the pro-
band’s DNA and one additional control, using primers that
contained restriction sites XhoI and EcoRV in their 50 ends.
PCR products and vector were digested with the two
enzymes and subsequently used in a ligation reaction, after
puriﬁcation with QIAquick PCR Puriﬁcation Kit (QIA-
GEN). The structure of the minigenes is shown in Fig. 1a.
After transformation of competent E. coli DH5a (Invitro-
gen), independent colonies were selected with minigenes
containing the variant allele from the patient, WT alleles
from the patient and from the controls. All constructs were
veriﬁed by sequence analysis and conﬁrmed the absence of
changes in the constructs. These minigenes and the empty
vector were transfected into HeLa cells. Transfection
was performed in duplicate with FuGENE HD transfec-
tion reagent (Promega) according to the manufacturer’s
protocol.
After RNA extraction from the transfected HeLa cells
and reverse transcription, the cDNA was ampliﬁed using
primers in each of the ﬂanking exons of the vector pSPL3b,
which we named A and B for clarity (Fig. 1a). The results
obtained are shown in Fig. 1b. The WT allele of the patient
and of a healthy control show only one band in the agarose
gel, with a larger size than that observed for the empty
vector. Sequencing conﬁrmed that the RT-PCR products
contain exon 17 (Fig. 2). The variant allele of the patient
shows a prominent lower band of the same size as the
empty vector indicating exon 17 skipping, which was
conﬁrmed by sequencing. In addition, a faint unexpected
upper band can be observed for the variant allele.
Sequencing of the two bands separately, by excision of the
bands from the gel, revealed this to be a transcript
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DOI 10.1007/s10549-011-1878-3Fig. 1 Ex vivo assay using
pSPL3b vector. a Structure of
the pSPL3b vector containing
exon 17 and ﬂanking intronic
regions with the mutant or wild-
type allele (c.4987-3C[G). The
size of the exon, intronic
regions and the restriction sites
included in the primers are
indicated. b Transcript analysis
by electrophoresis of the RT-
PCR products obtained after
transfection of HeLa cells using
primers hybridizing to the exons
of the vector. H2O negative
PCR control, MW molecular
weight ladder XIV (Roche).
Boxes next to the PCR bands
indicate the exon composition
and the position of the primers
used is shown with arrows
Patient
(c.4987-3C)
Control
(c.4987-3C)
Patient
(c.4987-3G)
Upper band
Exon B from pSPL3b
Exon B from pSPL3b
Exon B from pSPL3b
BRCA1 exon 17
BRCA1 exon 17
CATGCTGGCCAGGATGGTCTCGATCTCCT Intron 17
TGCTGGGTCGACTCTAGAGCGTGCAGCTT Exon A pSPL3b
Exon A from pSPL3b Exon B from pSPL3b Patient
(c.4987-3G)
Lower band
Fig. 2 Reverse sequence of
ampliﬁcation products observed
in Fig. 1b, using primers in the
exons A and B of the pSPL3b
vector. The two fragments of
the sample containing the
c.4987-3G variant were excised
from the gel and sequenced
separately. As expected, both
the samples with WT sequence
c.4987-3C contain exon 17.
Vector containing the c.4987-
3G variant gave rise to a
transcript where the exons of the
vector are adjacent, revealing
exon 17 skipping (lower band,
Fig. 1b), and another transcript
with inclusion of part of intron
17 (upper band, Fig. 1b). The
latter contained a heteroduplex
of the two described transcripts,
which formed due to the high
similarity between the two
fragments
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123containing part of intron 17. In Fig. 2, the sequence of this
transcript is shown but it contains a background sequence
of the transcript lacking exon 17 (the lower band on the
gel). This is due to heteroduplex formation between the
two fragments, which occurs due to the high similarity
between them as both contain exons A and B. The intron
17 retention starts at the beginning of intron 17, position
c.5074?1, and the donor splice site is at position
c.5074?153. This is possible since the original donor
splice site of exon 17 is also predicted to be a strong
acceptor splice site (AG|GTATAC, 76% score) by the
Splice Site Finder-like algorithm and Human Splice Finder
(recently added to the Alamut software), as observed using
Alamut (Interactive Biosoftware), which integrates several
splice site prediction algorithms. The c.5074?153 is pre-
dicted to be a weak donor splice site by two algorithms
(5 and 11% by MaxEntScan and GeneSplicer, respectively)
but strongly predicted by the Human Splice Finder algo-
rithm (79%). This intronic region is not observed in the
WT alleles used in the ex vivo assay, neither in the pre-
vious results from the IL2/PHA stimulated lymphocytes.
We conclude that the intron retention is an artefact in the in
vitro system caused by skipping of exon 17 and activation
of cryptic splice sites.
Summarising, using an ex vivo assay to complement the
previous RT-PCR analysis on RNA from IL2/PHA stimu-
lated lymphocyte cultures [1], we were able to show that
the variant allele from the patient results only in exon 17
skipping since a transcript containing exon 17 was not
detected. The deletion of BRCA1 exon 17 is a frameshift
event that leads to a truncated protein: p.Val1665Ser-
delfsX9. In combination with the results from the previ-
ously reported RT-PCR analysis, we are now conﬁdent that
the BRCA1 c.4987-3C[G variant is pathogenic and can be
genetically counselled as such.
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